

SENESCO TECHNOLOGIES INC

Form 8-K

October 24, 2013

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 23, 2013

Senesco Technologies, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction
of Incorporation)

001-31326

(Commission File Number)

84-1368850

(IRS Employer Identification No.)

Edgar Filing: SENESCO TECHNOLOGIES INC - Form 8-K

721 Route 202-206, Suite 130, Bridgewater, NJ H8807
(Address of Principal Executive Offices) (Zip Code)

(908) 864-4444
(Registrant's telephone number,

including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Item 8.01 Other Events.

On October 23, 2013, Senesco Technologies, Inc. (“Senesco” or the “Company”) issued a press release announcing the treatment of the first patient at the Company’s newly opened clinical-trial site at Seattle Cancer Care Alliance (SCCA). This patient is part of Senesco’s Phase 1b/2a clinical study of its therapeutic drug candidate, SNS01-T, targeting B-cell cancers.

SCCA is a cancer treatment center that unites physician scientists from Fred Hutchinson Cancer Research Center, UW Medicine and Seattle Children’s. The organization strives to provide outstanding care to cancer patients and to further improve survival rates. By bringing together the cancer-related patient-care services of the three institutions, SCCA builds on existing strengths, allows easier interactions among the cancer experts in each organization and provides improved access to resources.

The study is an open-label, multiple-dose, dose-escalation study, which is evaluating the safety and tolerability of SNS01-T when administered by intravenous infusion to approximately 15 relapsed or refractory multiple myeloma, mantle cell (MCL) or diffuse large B-cell lymphoma (DLBCL) patients. While the primary objective of this study is to evaluate safety and tolerability, the effect of SNS01-T on tumor response and time to relapse or progression will be assessed using multiple well-established metrics including measurement of monoclonal protein in multiple myeloma and CT imaging in MCL and DLBCL.

A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press Release of Senesco Technologies, Inc. dated October 23, 2013.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**SENESCO
TECHNOLOGIES, INC.**

Dated: October 24, 2013 By: /s/ Leslie J. Browne, Ph.D.

Name: Leslie J. Browne,

Ph.D.

Title: President and Chief
Executive Officer